John S. Stafford III Acquires 3,400 Shares of Xencor, Inc. (XNCR) Stock
Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III bought 3,400 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were purchased at an average cost of $19.89 per share, with a total value of $67,626.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Xencor, Inc. (XNCR) opened at $20.29 on Wednesday. Xencor, Inc. has a 52-week low of $18.55 and a 52-week high of $29.38.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/john-s-stafford-iii-acquires-3400-shares-of-xencor-inc-xncr-stock/1704471.html.
A number of research analysts have weighed in on the stock. Canaccord Genuity reissued a “buy” rating and set a $36.00 target price on shares of Xencor in a research report on Tuesday, August 8th. Zacks Investment Research lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine raised shares of Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 price objective on shares of Xencor in a research report on Sunday. Finally, BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. Xencor has an average rating of “Hold” and a consensus target price of $30.25.
Institutional investors and hedge funds have recently made changes to their positions in the company. Equitec Specialists LLC bought a new stake in Xencor in the second quarter valued at about $116,000. Great West Life Assurance Co. Can increased its stake in Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,005 shares during the period. SG Americas Securities LLC increased its stake in Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 3,252 shares during the period. Legal & General Group Plc increased its stake in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares during the period. Finally, Principal Financial Group Inc. bought a new stake in Xencor in the third quarter valued at about $201,000. 76.70% of the stock is owned by institutional investors and hedge funds.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.